503A vs 503B Compounding Pharmacies: The Complete 2026 Guide

Almost every hard question in compounding (who can make what, in what quantity, for whom, and under whose inspection) comes back to two short numbers in the Federal Food, Drug, and Cosmetic (FD&C) Act: 503A and 503B. Get the distinction right and the rest of the space falls into place: office stock, beyond-use dates, what a Certificate of Analysis actually proves, where compounded peptides and GLP-1s stand in 2026. Get it wrong and you either fill a prescription you shouldn't or turn away business you legitimately could have served.

This guide lays out both designations from the primary sources, then maps them onto the questions pharmacy operators and prescribers are actually asking this year.

This is educational, not legal advice. Regulatory statements are date-stamped; the peptide and GLP-1 rules moved through 2026, so re-verify the linked FDA sources against the current date before you rely on any point.

The core distinction: patient-specific prescription vs. batch office stock

The cleanest way to hold the difference in your head is by who the medication is made for.

• Section 503A covers traditional, patient-specific compounding. A licensed pharmacist (or physician) compounds a drug for an identified individual patient pursuant to a valid prescription. The classic community and specialty compounding pharmacy operates under 503A.
• Section 503B created a category that didn't formally exist before the 2013 Drug Quality and Security Act: the outsourcing facility. A 503B facility can compound in bulk, without a patient-specific prescription, and sell that stock to healthcare facilities for office use, meaning the vials a clinic keeps on the shelf to administer in-house.

The FDA states the split plainly in its overview of the FD&C Act provisions that apply to human drug compounding: 503A is the patient-specific route with exemptions from certain FDA requirements; 503B is the voluntary outsourcing-facility route that trades broader manufacturing-style obligations for the ability to produce office stock at scale.

So the first fork is almost always this: is there a prescription for a named patient (503A), or is this stock a facility will keep on hand and administer (503B)?

Regulatory oversight: state boards + USP vs. FDA + cGMP

The two designations answer to different masters, and this is where the operational reality diverges most.

503A: primarily state boards of pharmacy, under USP standards

A 503A pharmacy is regulated first and foremost by its state board of pharmacy, and it is expected to compound in accordance with the applicable United States Pharmacopeia (USP) compounding chapters, notably USP <795> (nonsterile) and USP <797> (sterile) preparation standards. In exchange for meeting the 503A conditions, these preparations are exempt from certain federal requirements that apply to manufactured drugs, including current Good Manufacturing Practice (cGMP) and new-drug approval. The FDA can and does still inspect, but day-to-day oversight lives largely at the state level.

503B: registered with and inspected by the FDA, under cGMP

An outsourcing facility registers with the FDA, is subject to routine, risk-based FDA inspection, must comply with cGMP, and reports adverse events and product listings to the agency. In effect a 503B facility operates much closer to a small drug manufacturer than to a corner compounding pharmacy. The FDA's compounding inspections and oversight FAQ describes how the agency applies these differing expectations across the two categories.

The shorthand, cGMP vs. USP compounding, is a useful mnemonic, but it oversimplifies. USP standards still bind a 503A pharmacy, and a well-run 503A operation takes them seriously. The point is that cGMP is the higher, manufacturing-grade bar that 503B facilities must clear, and it is what lets them make batch stock without a prescription in hand.

Distribution & use: home dispensing vs. office stock, and beyond-use dates

Because of who each product is made for, the two designations distribute differently.

• 503A output is dispensed against a prescription for a specific patient, typically shipped or handed to that patient (or their caregiver) for home use. There is no legitimate "make 100 vials and hold them for whoever walks in" under 503A; quantities are tied to the individual prescription and reasonable anticipated need.
• 503B output can be sold as office stock to clinics, hospitals, and physician practices without a patient-specific prescription, for administration in the facility. This is the answer to a question operators ask constantly: can a 503A pharmacy sell office stock? Generally, no. Non-patient-specific office stock is the 503B/outsourcing-facility lane. A 503A pharmacy that wants to serve office-stock demand typically needs a 503B facility (or a partner that has one).

Beyond-use dating (BUD)

A compounded preparation is not a manufactured drug with a multi-year shelf life. It carries a beyond-use date (the date after which it should not be used) that is generally shorter and driven by the formulation, the preparation environment, and the applicable USP chapter. Sterile preparations in particular have tighter BUDs than a mass-produced sterile drug. Practically, BUD shapes how much a 503A prescriber should order at once, and how a 503B facility must plan batch production and distribution so stock is used well within date. Whichever route, "how long is this good for, and why" is a question the paperwork should answer on its face.

Quality & testing: what a COA means in each context

A Certificate of Analysis (COA) is the batch-level record of what was actually made: identity, strength/potency, and purity, verified by testing. It is among the most useful objective quality signals in compounding, but what it represents differs by designation:

• In a 503A context, COAs most often attest to the active pharmaceutical ingredients and components used, alongside the pharmacy's USP-conformant processes and any potency/sterility testing the preparation warrants. It tells a prescriber that the raw materials and the specific preparation meet spec.
• In a 503B context, COAs sit inside a full cGMP quality system, alongside batch records, validated processes, stability data, and release testing, so the COA is one artifact in a manufacturing-grade documentation chain.

For prescribers and pharmacy buyers, the discipline is the same regardless of route: don't accept a compound you can't tie to a current, matching COA. If you want the deeper mechanics of reading and verifying one, this primer on the Certificate of Analysis is a solid starting point. The absence of a batch-matched COA is a red flag in either lane.

Where peptides and GLP-1s land across the two in 2026

This is the section that dates fastest, so read the timestamps.

Compounded GLP-1s (semaglutide, tirzepatide, liraglutide): as of mid-2026

The shortage-era allowance that let many pharmacies and outsourcing facilities produce compounded GLP-1 copies has ended. The FDA removed semaglutide from its drug shortage list in February 2025, and in April 2026 the agency proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk-drug substances list, with a public comment period that ran into mid-2026. That move is aimed squarely at the 503B office-stock route for these molecules. The practical, defensible path for these drugs now runs through 503A patient-specific compounding with a documented clinical rationale, rather than batch production in anticipation of orders. Because this is a proposal under comment, treat the specifics as live and confirm against the current FD&C Act compounding provisions. For the full prescriber walkthrough, covering rationale, documentation, and sourcing, see our guide to how to prescribe compounded semaglutide in 2026.

Peptides (BPC-157, TB-500, KPV, MOTS-C): as of mid-2026

Several research peptides were reclassified off the FDA's Category 2 list in 2026, which generated a wave of "peptides are legal now" content. That framing is wrong in a way that matters for a compounding pharmacy: removal from Category 2 is not the same as FDA approval, and it is not the same as 503A eligibility. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed several of these peptides for 503A eligibility at its July 23-24, 2026 meeting, but a compound generally becomes eligible to compound only once the FDA formally acts to list it. Until then, the honest status for many of these is "reviewed, not yet resolved." We break down what each of those three statuses means, and why conflating them is a compliance risk, in our 2026 BPC-157 and peptide reclassification guide for prescribers.

Category 2 removal ≠ FDA approval ≠ 503A eligibility. Three separate hurdles. A compound can clear the first without being anywhere near the third.

When a provider needs 503A vs. 503B

Strip away the jargon and the decision is usually simple:

• Choose 503A (patient-specific) when you are treating an individual patient. The compound is written for a named person, dispensed for home use, and there's a clinical reason a compounded formulation is needed for that patient. This is the default for most outpatient, telehealth, and specialty prescribing.
• Choose 503B (office stock) when a facility needs ready-to-administer stock on the shelf: vials kept on hand to administer during visits, where writing a patient-specific script for each dose isn't practical and cGMP-grade batch product is warranted.

Many practices need both at different moments: patient-specific compounds shipped to patients' homes, and a small amount of office stock for in-visit administration. That dual need is why the sourcing question ("does my partner support both channels?") matters as much as the clinical one.

How a marketplace can serve both channels

Historically, serving both lanes meant maintaining two very different relationships: a 503A pharmacy for patient-specific dropship, and a separate 503B outsourcing facility for office stock. That's operational drag on both sides: providers juggle vendors, and pharmacies chase demand across fragmented channels.

A marketplace collapses that. PEPTPlus connects verified compounding pharmacies with prescribing providers across both the 503A patient-specific and the 503B office-stock channels through a single listing. For a pharmacy, that means:

• One catalog, both channels. List your compounds and COAs once; get matched to patient-specific dropship scripts and office-stock demand, without standing up separate sales motions for each.
• Eligibility enforced by data. The catalog only surfaces compounds that are legally prescribable, so eligibility gray areas (peptides under review, GLP-1 route restrictions) don't turn into filled scripts they shouldn't be.
• State-license routing. Scripts route only to a pharmacy licensed in the patient's state, matched by purity, price, and delivery time, automatically and auditably.
• COA-backed provenance on every batch, captured against the record. It's the trust signal providers increasingly demand before they'll route volume to you.

If demand generation is your real bottleneck, that's a whole discipline of its own. Our guide on how to get more prescriptions for your compounding pharmacy covers winning prescriber referrals without a rep network. But the structural point is this: you don't have to choose which channel to build for. You can become a partner pharmacy and serve patient-specific and office-stock demand from the same verified listing. The PEPTPlus pharmacy overview walks through how the matching, COA, and payout flow works end to end.

Quick reference: 503A vs 503B at a glance

• Made for whom: 503A, a named patient with a prescription. 503B, batch stock, no patient-specific prescription required.
• Primary oversight: 503A, state boards + USP. 503B, FDA registration + inspection under cGMP.
• Office stock: 503A, generally no. 503B, yes, this is the lane for it.
• Distribution: 503A, dispensed to the patient (often home use). 503B, sold to facilities for in-office administration.
• Beyond-use dating: Both carry BUDs shorter than a manufactured drug; sterile preparations are tightest.
• COA: Non-negotiable in both. Always tie the compound to a current, matching batch COA.

For a plain-English cross-check of these designations, the FDA Group's 503A vs 503B quick guide and Fagron's comparison of 503A and 503B similarities and differences both walk the same ground from an industry perspective.

Serve both channels from one verified listing

Whether your patients need patient-specific compounds shipped to their door or your clinic partners need office stock on the shelf, the underlying job is the same: verified quality, correct licensure, and provenance you can prove. PEPTPlus turns that into matched, pre-qualified demand across both the 503A and 503B channels, with $0 per-script cut and your prices set by you.

Become a partner pharmacy →

Prescriber weighing which route you need? Start at the PEPTPlus provider platform overview to see how patient-specific and office-stock ordering work in one place.